Physician profile

Dana Hoffman

Corinth, MS

NPI 1346943867

$334.10

in general payments reported to CMS, 2019-2025

5 companies · $288 in 2025

The $288 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$334.10

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Madrigal Pharmaceuticals $149.86 2025 Rezdiffra
Novo Nordisk INC $124.61 2025
Merck Sharp & Dohme LLC $24.00 2023
Angiodynamics, INC. $22.05 2023 Auryon Laser System 100-120 Vac
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $13.58 2025 Caplyta

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dana Hoffman

$334.10

in general payments reported 2019-2025

Years
2023-2025
Top company
Madrigal Pharmaceuticals
Context
The $288 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11550555/dana-hoffman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.